Novartis has secured European Commission approval for Itvisma for the treatment of children aged two years and older, as well ...

Applications have opened for the ninth cohort of KQ Labs, the national accelerator for data‑driven health start‑ups delivered ...

AlzeCure Pharma has signed an out‑licensing and collaboration agreement with Danish biotech QuantumCell ApS, granting global ...

R1 Therapeutics has formed a scientific advisory board comprising seven internationally recognised nephrology experts as the ...

Agomab Therapeutics has announced the design of its phase 2b NOV‑ERA study of ontunisertib in fibrostenosing Crohn’s disease, ...

Lundbeck will present new migraine data at the European Academy of Neurology Congress 2026, taking place from 27–30 June in ...

Racura Oncology has treated the first patient in its phase 1 HARNESS‑1 clinical trial of RC220 for EGFR‑mutant non‑small cell ...

The European Commission has approved Sanofi’s Cenrifki (tolebrutinib) for adults with secondary progressive multiple ...

Early trial shows more than 50% LRRK2 reduction and supports expansion into other neurodegenerative conditions Arvinas has announced encouraging phase 1 data for its investigational PROTAC degrader ...

Company secures first commercial product with data for active and chronic TED Viridian Therapeutics has received US FDA approval for Lumvoa (veligrotug-vvze) for thyroid eye disease, marking the first ...

PharmaTimes is the UK’s leading pharmaceutical magazine, tracking the trends and issues that affect the industry here in the UK, in Europe and across the world. We deliver independent, authoritative ...

Early safety and efficacy signals support move into repeat‑dose phase 2a trial PulseSight Therapeutics has unveiled positive phase 1 results for PST‑611, its non‑viral gene therapy candidate for dry ...